



PHARMACEUTICAL REGULATORY AGENCIES OF INDIA

Syeda Rakhshinda Zareen*¹, Dr. Osman Ahmed¹, Reshma¹, Mohammed Sayeed Uddin¹ and Dr. Anas Rasheed²

¹Department of Pharmaceutical Analysis, Deccan School of Pharmacy, Hyderabad.

²CSO, Gaelib Medications Private Limited, Hyderabad.

***Corresponding Author: Syeda Rakhshinda Zareen**

Department of Pharmaceutical Analysis, Deccan School of Pharmacy, Hyderabad.

Article Received on 08/12/2022

Article Revised on 28/12/2022

Article Accepted on 18/01/2023

ABSTRACT

Pharmaceuticals have the potential to improve a nation's economy, save countless lives, and even assist prevent or control the spread of disease. This clarifies the need for monetary investment in medicine on the part of consumers, governments, pharmaceutical firms, and educational establishments alike. Yet this can only occur if there is confidence in the medicine's safety, effectiveness, and quality. This means the pharmaceutical sector, from discovery to production to retail, is under close watch to ensure the safety and efficacy of the drugs at every stage. To ensure that pharmaceuticals are effectively managed and to protect and improve public health, governments establish powerful National Regulatory Authorities (NRAs) to supervise the regulation of pharmaceuticals. Laws governing the production and distribution of pharmaceutical products are crucial to preserving public health and preventing damage from substandard medicines. The pharmaceutical regulatory agency is responsible for enforcing laws and offering guidelines in the following areas: drug development, licencing, registration, manufacture, labelling, storage, marketing, distribution, price, import, and post-market research. Pharmaceutical businesses that aim for a worldwide market are also subject to the often more stringent regulations of other governments. One regulatory approach for a medical product's Marketing Authorization Application (MAA) that may be utilised in several countries may be difficult to identify. The electronic submission of applications for pharmaceutical registration is now standardised thanks to Common Technical Document (CTD). This article provides an overview of the pharmaceutical sector regulatory agency in India.

KEYWORDS: Regulatory Agency, CDSCO, US FDA, EMA, Marketing Authorization Application, Common Technical Document.

INTRODUCTION

Governments use pharmaceutical laws, a set of legal, administrative, and technical procedures designed to guarantee the public's safety, the medicines' efficacy and quality, and the relevance and accuracy of product data. The term "regulation"^[1] encompasses a wide range of legally binding and authoritative guidelines, proposals, procedures, laws, etc. New and pre-owned, domestically produced and imported goods, all must adhere to these standards. Regulators work to ensure that medicines remain of high quality at every level of the production process.^[2] An successful medical regulatory system ensures timely patient access to safe and effective pharmaceuticals and promotes research into new therapies.^[3,4] The goal of regulatory organisations is to facilitate the timely development and delivery of safe and effective pharmaceuticals and healthcare products to the public by providing strategic, tactical, and operational guidance and help for conforming to regulations. The pharmaceutical industry nowadays is extremely organised, systematic, and regulated. Numerous accidents, such as those involving

sulphanilamide elixir, vaccinations, and thalidomide, drove home the need for a well controlled system. As a result, high-quality medical supplies may be mass-produced and disseminated with less difficulty.^[4]

International Regulatory Agencies and Organizations

The World Health Organization (WHO), the Pan American Health Organization (PAHO), the World Trade Organization (WTO), and the World Intellectual Property Organization (WIPO) all play important roles in the enforcement of laws and regulations pertaining to the development, registration, production, distribution, marketing, pricing, and study of pharmaceutical products. They guarantee and improve the execution of legislation in previously unregulated territories, which is a boon to public safety.^[5] There is a drug regulating body in India called the Central Drugs Standard Control Organization (CDSCO). CDSCO is India's primary regulatory agency. The Directorate General of Health Services, which is part of the Indian Ministry of Health and Family Welfare, is responsible for the organization's funding and management (DGHS). The CDSCO is the

principal regulatory organisation for carrying out federal government tasks under the Drugs and Cosmetics Act. CDSCO's headquarters are located in New Delhi. CDSCO and state regulatory authorities work together to provide licences for transfusions of blood and blood products, intravenous fluids, vaccines, and sera. The Drug Controller General of India (DCGI) is in charge of drug and medical device surveillance on behalf of CDSCO. For guidance, the DCGI looks to the Drug Consultative Committee and the Drug Technical Advisory Board (DTAB) (DCC). The CLA's role is to provide the go-ahead on the licencing and classification of medical devices (CLAA). It's also accountable for determining and enforcing safety standards, doing post-market monitoring, and issuing warnings and recalls when issues are found with pharmaceutical products.^[5-7]

Functions of CDSCO

• Central licencing authorities are responsible for

- ♣ New drugs approval
- ♣ Performing clinical trials
- ♣ Establishing standards for drugs
- ♣ Quality Control of imported drugs, import registration and licencing
- ♣ Coordination of the activities of state drug control authorities by giving expert opinion to uniformly enforce the D&C Act.

• State licencing authorities are responsible for

- ♣ Regulation of production, sale and marketing of drugs.

• Other Functions

- ♣ Legalization of the Commercialization of Blood, Vaccines, Recombinant DNA Products, and Selected Medical Devices.

Adjustments to the Rules Implementing the D&C Act.

All three of these export authorization documents (Export Test License, Personal License, and No Objection Certificate) are issued. Older pharmaceuticals and cosmetics should be outlawed.

Preclinical testing and assessment of cosmetics and medicines Functions of Drug Testing Centers Centrally.^[6]

Responsible for making the ultimate decision in disputes concerning medicine quality allegations.

Substances used for pharmaceutical analysis and microbiological cultures utilised to produce national reference standards Obtaining, storing, and disseminating pharmacological compounds that serve as worldwide reference standards In addition, we provide pharmacies and quality control laboratories in states with reference materials including drugs and cultures.


Instruction of Drug Control Analysts for Government Agencies and Others.

Educating the global WHO workforce on state-of-the-art analytical methods.

Assists the federal drug control authorities with licencing decisions by offering opinions on drug safety and effectiveness. Analytical requirements need to be developed in order to create monographs for the Indian Pharmacopoeia and the Indian Homoeopathic Pharmacopoeia.

In addition, the CDL works with the WHO to create the norms and criteria for the International Pharmacopoeia.

Research and analysis of medicines and cosmetics also fall within the purview of this role, as do tasks such as analysing registration samples for site registration approval in compliance with Good Manufacturing Practices (GMP). Regulatory Procedures for New Drugs in India: Before a company may manufacture or import a novel pharmaceutical, it must first get clearance from the licencing authority (DCGI) by submitting a properly completed Form 44 and the supporting documentation specified in Schedule Y of the D&C Act of 1940. There is a representation of India's process for approving new medications. If an imported pharmaceutical has to be shown to be effective and safe for use by the Indian population, clinical investigations must be conducted and a report produced in line with Schedule Y standards. In the event that the application meets all requirements, DCGI will approve it.^[7]



Schedule Y of D&C Act 1940 and Rules 1945

Clinical trials of all phases are required for therapeutic compounds discovered in India under Section 2.4 (a) of Schedule Y.

According to Section 2.4 (b) of Schedule Y, the applicant must present the data available from other countries for drug compounds identified in other countries, and the licencing authority may require him to repeat all the studies or approve him to continue from Phase III, depending on the circumstances.

Phase III clinical trials may be required by the licencing body, but only after the applicant has completed pharmacokinetic studies (bioequivalence studies) to demonstrate that data gathered from the Indian population is consistent with data produced in other populations (Section 2.8 of Schedule Y).

The amount of confidence the licencing authority has in a medicine will influence the kind of clinical trials that will be required to establish the drug is safe and effective in a certain situation. India's New Drug Application process is just as rigorous and time-consuming as the FDA's.^[6-7]

Some clinical trials may be waived under Rule 122A of the D&C Act of 1940 if: • the licensure authority determines it is in the public interest; • import permission for drugs may be granted based on data from clinical trials performed in other countries; • in the case of drugs which have been approved and are in widespread use in other countries.^[8]

Drugs & Clinical Trials New Rules 2019

Indian medicines will just need to wait one month for approval under the new rules, while products from other countries would have 90 days. The DCGI standards do not need a local Clinical Trial if a drug is already licenced for sale in one of the countries mentioned by the DCGI (CT). The DCGI will not impose CTs on medicines that have already been approved for sale in the European Union, the United Kingdom, Australia, Canada, Japan, or the United States. Clear and efficient rules for CT and speedy dissemination of novel drugs to the local population are two goals of the new legislation enacted in India to encourage clinical research.^[9]

CONCLUSION

The standards by which new drugs are approved in India are among the world's most stringent. The primary motivation for the development of pharmaceutical product standards was the need to safeguard public health. Regulatory bodies are responsible for ensuring that pharmaceutical companies conduct research and production of safe and effective drugs.

REFERENCES

1. Pierre-Louis Lezotre. Introduction. International Cooperation, Convergence and Harmonization of

- Pharmaceutical Regulations, Academic Press, 2014; 1-5.
- Nidhi B. Agarwal, Manoj Karwa. Chapter 12 - Pharmaceutical Regulations in India. Pharm. Med. Transl. Clin. Res, Academic Press, 2018; 215-231.
 - Alasdair Breckenridge, Kent Woods. Medicines regulation and the pharmaceutical industry. Br. Med. J, 2005; 331(7520): 834– 836.
 - Sri Harsha. Y, Sharmila Reddy. V, Mary. D, Nagarjunareddy. D, Nagabhusanam. M. V, Brahmaiah Bonthagarala. Role of Regulatory Affairs in a Pharmaceutical Industry. Int.J. Pharm. Res. Bio-Sci, 2017; 6(2): 170-177.
 - Mankar. S.D, Gholap. V.D, Zende. T.P, Dighe. R.S. Drug regulatory agencies in India, USA, Europe and Japan-a review. IJIPLS, 2014; 4(2): 288-297.
 - Central Drugs Standard Control Organization. Available at: <https://www.cdscoonline.gov.in/CDSCO/homepage>.
 - Anusha. T, Nagabhusanam. M.V. Role of regulatory affairs for new drug approval procedure in India. Int. J. of Pharmacy and Analytical Research, 2017; 6(2): 431-441.
 - Amar Jesani, Sandhya Srinivasan. New Drugs and Clinical Trials Rules, 2019: The market trumps ethics and participant rights. Indian J Med Ethics, 2019; 4(2): 89-91.
 - The Gazette of India, New Drugs and Clinical Trial Rules, 2019. Available at: www.iscr.org
 - U.S. Food and Drug Administration. Available at: www.fda.gov.
 - Jawahar. N, Vidhya Lakshmi. T. Regulatory Requirements for the Drug Approval Process in US, Europe and India. J. Pharm. Sci. Res., 2017; 9(10): 1943-1952.
 - Gail A.Van Norman. Drugs, Devices, and the FDA: Part 1: An Overview of Approval Processes for Drugs. JACC Basic Transl Sci., 2016; 1(3): 170-179.
 - Prajapati Vishal, Goswami Rahulgiri, Makvana Pratik, Badjatya Jitendra Kumar. A review on drug approval process for US, Europe and India. Int. J. Drug Regul, 2014; 2(1): 1-11.
 - Saffiya khatun. M, Jyothshna Devi Katamreddy, Jayachandra Reddy. P.A review on ANDA submission requirements for Generic drugs: "Paragraph IV certification" as per FDA CDER guidelines. Int. J. Drug Regul, 2018; 6(3): 5-12.
 - Pratik Makvana, Dilip Maheshwari. Regulatory Requirements for Marketing Authorization of Generic Parenteral Product in European Countries by Decentralised Procedure. J Pharm Sci Bioscientific Res, 2014; 4(2): 145-149.